Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
|
|
- Erick Austin
- 8 years ago
- Views:
Transcription
1 Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We suggest that patients with diabetes mellitus aim to achieve an HbA1c <7.0% or <53 mmol/mol* (2B). * SI units recommended as per The International HbA1c Consensus Committee [1, 2] UNGRADED SUGGESTIONS FOR CLINICAL CARE There are no ungraded statements IMPLEMENTATION AND AUDIT KCAT education programs for primary health care providers should incorporate the CARI Early CKD Diabetes Mellitus recommendations. Primary health care practitioners should regularly audit their practices to ascertain the proportion of their diabetic patient population that meets the KHA-CARI Early CKD Guideline HbA1c targets for primary prevention of CKD. BACKGROUND Diabetes mellitus (DM) is well-recognised as a risk factor for development of chronic kidney disease (CKD). Furthermore, amongst patients with DM glycaemic control, most commonly assessed by measurement of the glycosylated haemoglobin (HbA1c) modulates the risk of developing diabetic nephropathy. In particular, elevated HbA1c levels increase the likelihood of renal disease. Several treatments for DM are available. These include oral hypoglycaemic agents (sulfonylureas, glitinides, metformin, glitazones, α-glucosidase inhibitors), incretin enhancers and mimetics, and insulin. Available insulin preparations include very short-, short-, intermediate- and long-acting agents. While all diabetic treatments aim to reduce blood glucose levels they have a diverse range of mechanisms of action with potential benefits and harms that extend beyond their glucose lowering activity. These differences may translate into variable effects on clinical outcomes. In this Guideline the currently available evidence regarding the role of treatment of DM in primary prevention of CKD is evaluated. Particular emphasis is placed on the relationship between glycaemic control and development of CKD, and on benefits of specific treatment regimens. SEARCH STRATEGY Databases searched: Text words for chronic kidney disease were combined with MeSH terms and text words for diabetes mellitus. The search was carried out in Medline (1966 August 2009). No language restrictions were placed on the search. The conference proceedings of the American Society of Early Chronic Kidney Disease July 2012 Page 1 of 9
2 Nephrology from were also searched for trials. Search update was carried out in Medline ( ). Text words and MeSH terms for kidney disease and renal insufficiency were combined with text words and MeSH terms for diabetes mellitus and glycosylated haemoglobin. Date of search/es: August 2009; February 2012 WHAT IS THE EVIDENCE? Trial (DCCT) was a multicentre, randomised trial comparing intensive versus conventional insulin therapy in 1441 patients with Type I DM (Insulin-requiring diabetes mellitus; IDDM) [3]. The study population was divided into 2 cohorts, primary prevention and secondary intervention. Inclusion criteria for the primary prevention cohort were urinary albumin excretion (UAE) less than 40mg per 24 hours, IDDM for 1 to 5 years, and absence of retinopathy. A total of 726 patients met the inclusion criteria for primary prevention, of which 378 were randomised to conventional therapy and 348 to intensive therapy. Baseline creatinine clearance was 127±28 vs 128±30 ml/min in the conventional and intensive therapy groups, respectively, and UAE 12±8 vs12±9 mg/24 hours. Patients in the primary prevention cohort had a significantly lower HbA1c beyond baseline. The mean follow-up was 6.5 years (range 3-9). The number of patients who developed microalbuminuria (defined by the authors as UAE 40mg/ 24 hours, measured annually) was less in the intensive therapy group (P<0.001); the mean adjusted risk of microalbuminuria was reduced by 34% (P=0.04). Amongst the secondary intervention cohort who had baseline AER <40mg/ 24 hours, intensive therapy reduced the adjusted mean risk of developing microalbuminuria by 43% (P=0.001). In the entire study population advanced nephropathy (UAE 300mg/24 hours, creatinine clearance <70mL/min/1.73m 2 ) developed in 7 patients (2 in the intensive therapy and 5 in the conventional therapy group). Severe hypoglycaemic episodes were more common in the intensive therapy group. The Epidemiology of Diabetes Interventions and (EDIC) was a long-term follow-up study of a subgroup of participants in the DCCT [4]. The 1349 patients (688 and 687 in the former conventional and intensive treatment cohorts respectively) were followed for a further 7 or 8 years at completion of the DCCT. During the course of the EDIC study the mean HbA1c levels in the two cohorts approached each other but remained statistically different (8.0 vs 8.2% for the intensive and conventional groups respectively, P=0.002). In patients who had normoalbuminuria (AER <28 µg/min or 40 mg/24 hours) at DCCT commencement and completion, 6.8% of the former intensive therapy group developed microalbuminuria (AER >40mg/24 hours) compared to 15.8% of the former conventional therapy group. Albuminuria (AER >300mg/24 hours) developed in 1.4% and 9.4% of atrisk patients in the former intensive and conventional treatment cohorts by EDIC completion. An increase in the serum creatinine to above 2 mg/dl (176.8 µmol/l) occurred in 0.7% of the intensive group and 2.8% of the conventional group (P=0.004). Statistically significant differences in the mean serum creatinine throughout the EDIC study were also observed (0.89 vs 0.92 mg/dl (78.7 vs 8.13 µmol/l), P<0.001). Despite more frequent hypoglycaemic episodes in the intensive treatment group there was no long-term effect on cognition [5]. The United Kingdom Prospective (UKPDS) was a randomised controlled trial conducted between 1977 and 1997 that compared conventional therapy (diet alone) with intensive therapy (insulin, glibenclamide, glipizide, metformin or chlorpropamide as monotherapy or combination therapy) in 3,867 patients with newly diagnosed type 2 diabetes [6, 7]. Median follow-up was 10.0 years. Data was presented separately for intensive therapy with insulin, sulfonylureas or chlorpropamide versus conventional therapy, and metformin versus conventional therapy. The median HbA1c was 7.0% for intensive therapy with insulin, chlorpropamide and sulfonylureas versus 7.9% conventional therapy, and 7.4% for metformin vs 8.0% for the conventional group. Amongst a subgroup of patients treated with chlorpropamide, glibenclamide or insulin, (and conventional therapy controls) microalbuminuria was consistently more common in the conventional therapy group from 9 years onwards. No difference in microalbuminuria was seen between metformin and conventional therapy. There was no difference in the number of patients developing renal failure (dialysis or plasma creatinine > 250 mol/l) or dying from renal disease either between conventional Early Chronic Kidney Disease July 2012 Page 2 of 9
3 and intensive therapy groups, or agents used in intensive therapy. Hypoglycaemic episodes were more common in patients receiving intensive therapy. A cohort of 3227 patients entered a post-trial monitoring study. After 10 years of monitoring there was no difference in the urinary albumin: creatinine ratio between intensive and conventional treatment [8]. Plasma creatinine levels were 15% higher in patients treated with metformin than other groups. Sasaki and colleagues retrospectively evaluated risk factors for development of persistent microalbuminuria ( 2 consecutive positive tests for urine albumin ( 30 mg/dl) measured by Albustix in one year, in the absence of other renal disease) in patients with Type 2 diabetes mellitus [9]. Patients were first seen in a Japanese medical clinic between 1960 and 1979, and followed until 1984 (average follow-up 10 years). In total 1196 patients (740 males, 456 females) were evaluated. The mean annual incidence rate of persistent microalbuminuria differed significantly according to the type of treatment patients were on at baseline (10.74% vs 19.47% vs 40.78% for diet, oral hypoglycaemic agents and insulin respectively, P<0.01). Treatment with insulin was an independent predictor for development of microalbuminuria on logistic regression analysis. Limitations of this study include the retrospective nature, and absence of information about glycaemic control other than fasting glucose at baseline. The study does not establish whether insulin therapy is associated with an increased risk of developing microalbuminuria because it is a surrogate marker of poor glycaemic control and/ or duration of DM. Applicability to current practice may be limited because this study was conducted in a Japanese population. SUMMARY OF EVIDENCE Despite the high risk of developing CKD in patients with DM and recommendations for good glycaemic control there is very little evidence regarding treatment of DM and prevention of CKD. Three studies have evaluated the relationship between diabetes management and prevention of CKD. The DCCT was a well-designed RCT involving a large number of patients. It showed that intensive treatment with insulin reduced the risk of developing microalbuminuria, although the definition of microalbuminuria differed to the current NKF definition. This benefit was sustained in a further 7-8 years of follow-up despite convergence of HbA1c levels. The overall rate of microalbuminuria in the DCCT/ EDIC cohort was lower than in other reported series, possibly due to a Hawthorne effect. This may reduce the applicability of the results to other populations. The relationship between glycaemic control and patient outcomes in type 2 diabetics was studied in the UKPDS trial. Microalbuminuria was less common with intensive therapy with glibenclamide, chlorpropamide or insulin than with conventional therapy, but no difference was seen with metformin therapy. Although a sustained beneficial effect of intensive therapy on overall patient outcomes was seen with intensive therapy following trial completion, this was not the case with renal outcomes. There is only one study addressing management of diabetes in the primary prevention of CKD. This was a retrospective cohort study with multiple limiting factors as discussed above. All studies in this area were commenced over 30 years ago. In light of modern treatment targets and newer therapeutic agents, this limits their applicability to current practice. WHAT DO THE OTHER GUIDELINES SAY? Kidney Disease Outcomes Quality Initiative:[10] 2.1 Target HbA1c for people with diabetes should be <7.0%, irrespective of the presence or absence of CKD (A) UK Renal Association: No recommendations. Canadian Society of Nephrology (CSN): [11] Targets for glycemic control, where they can be achieved safely, should follow standard Canadian Diabetes Association Guidelines (hemoglobin A1c < 7.0%, fasting plasma glucose 4 7 mmol/l) (grade B). Early Chronic Kidney Disease July 2012 Page 3 of 9
4 Glycemic control should be part of a multifactorial intervention strategy addressing blood pressure control and cardiovascular risk and promoting the use of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers, statins, and aspirin (grade A) Metformin is recommended for most type 2 diabetic patients with stage 1 and 2 CKD who have stable renal function unchanged over the prior months (grade A) Metformin may be continued in individuals with stable stage 3 CKD (grade B) Tailor the choice of other glucose-lowering agent(s) (including insulin) to the individual, the level of renal function, and comorbidity (grade D, opinion) Risk of hypoglycemia should be assessed regularly in individuals taking insulin or insulin secretagogues, and these patients should be taught how to recognize, detect, and treat hypoglycemia (grade D, opinion). European Best Practice Guidelines (EBPG): No recommendations. International Guidelines: No recommendations. SUGGESTIONS FOR FUTURE RESEARCH 1. Future research should focus on different treatment goals and development of CKD, particularly in patients with type 2 DM. 2. Studies of different therapeutic agents should be performed with a view to assessing whether nonglucose lowering effects of agents impact on the risk of developing CKD. 3. Studies should have long-term follow-up (many years) in light of the natural history of diabetic nephropathy. CONFLICT OF INTEREST Graeme Turner and Kate Wiggins have no relevant financial affiliations that would cause a conflict of interest according to the conflict of interest statement set down by CARI. David Johnson has a level II b. conflict of interest for receiving speaker honoraria and advisor s fees from several companies related to anaemia, CKD-MBD, hypertension and cardiovascular disease between 2008 and Early Chronic Kidney Disease July 2012 Page 4 of 9
5 REFERENCES 1. Hanas R and John G, on behalf of the International HbA 1c Consensus Committee, Consensus Statement on the Worldwide Standardization of the Hemoglobin A1c Measurement. Pediatr Diabetes. 2010; 11: Jones GRD, Barker G, Goodall I et al. Change of HbA1c reporting to the new SI units. Med J Aust. 2011; 195: DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Trial Research Group. N Engl J Med. 1993; 329: EDIC, Writing Team for the Diabetes C, Trial/Epidemiology of Diabetes I et al. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and (EDIC) study. J Am Med Assoc. 2003; 290: Jacobson AM, Musen G, Ryan CM et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007; 356: UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).. Lancet. 1998; 352: UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).. Lancet. 1998; 352: Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: Sasaki A, Horiuchi N, Hasagawa K et al. Persistent albuminuria as an index of diabetic nephropathy in type 2 diabetic patients in Osaka, Japan-incidence, risk factors, prognosis and causes of death. Diabetes Res Clin Pract. 1989; 7: National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49 (suppl 2): S1-S Levin A, Hemmelgarn B, Culleton B et al. Guidelines for the management of chronic kidney disease. Can Med Assoc J. 2008; 179: Early Chronic Kidney Disease July 2012 Page 5 of 9
6 APPENDICES Table 1. Characteristics of included studies Study ID N Study design Participants Follow up Comments and results Trial Research Group (1993) [DCCT] [3] RCT 6.5 years (average) 726 = primaryprevention cohort 715 = secondaryintervention cohort Patients with insulin dependent diabetes mellitus (IDDM), 13 to 39 years old, 726 had no retinopathy at baseline (the primary prevention cohort) and 715 had mild retinopathy (the secondary intervention cohort) In the primary-prevention cohort, intensive therapy reduced the adjusted mean risk for retinopathy development by 76% (95% CI: 62 to 85%; P<0.001) as compared to conventional therapy. In the secondary-prevention cohort, intensive therapy: Slowed the progression of retinopathy by 54% (95% CI: 39 to 66%; P<0.001) Reduced the development of proliferative or severe non-proliferative retinopathy by 47% (95% CI: 14 to 67%; P= 0.011) In the two cohorts combined, intensive therapy reduced the occurrence of: Microalbuminuria by 39% (95% CI: 21 to 52%) Albuminuria by 54% (95% CI: 19 to 74%) Clinical neuropathy by 60% (95% CI: 38 to 74%) Intensive therapy delays the onset and slows the progression of diabetic retinopathy, nephropathy and neuropathy in patients with IDDM. Two-to-three fold increase in severe hypoglycaemia was the main adverse event. Trial / Epidemiology of Diabetes Interventions and Research Group (2003) [EDIC] [4] Observational cohort Follow-up of the same cohort from the DCCT study in 28 medical centres USA and Canada (1993) 687 in the former intensive - treatment group 688 in the former conventional - treatment group 7 to 8 years Outcome measures for the follow-up comparison between the former intensive-treatment group and the former conventional-treatment group respectively. HbA1c level: 8% compared to 8.2% (P=0.002) Microalbuminuria: 6.8% compared to 15.8% Clinical albuminuria: new cases 1.4% compared to 9.4% Hypertension: 29.9% compared to 40.3% (P<0.001) Serum creatinine level of 2mg/dL or greater: 5 participants compared to 9 (P = 0.004) Conclusion: previous intensive treatment of diabetes with near-normal glycaemia during the DCCT study has an extended benefit in delaying progression of diabetic nephropathy. Early Chronic Kidney Disease July 2012 Page 6 of 9
7 Study ID N Study design Participants Follow up Comments and results 3,867 RCT Adult participants newly diagnosed with Type 2 Diabetes from 23 UK hospitals between 1977 and years HbA1c was 7.0% in the intensive group compared to 7.9% in the conventional group. Compared to the conventional group the risk in the intensive group was: - 12% lower for any diabetes-related end-point (95% CI: 1 to 21; P=0.029) - 10% lower for any diabetes-related death (95% CI: -11 to 27; P= 0.34) - 6% lower for all-cause mortality (95% CI: -10 to 20; P=0.44) There was a 25% risk reduction in microvascular endpoints (95% CI: 7 to 40; P=0.0099) Hypoglycaemic episodes: 0.7% in conventional treatment, 1.0% with chlorpropamide, 1.4% with glibenclamide and 1.8% with insulin. (1998)[7] Holman et al (2008) [8] 2,241 RCT Overweight participants recruited to UKPDS in 15 centres, with newly diagnosed Type 2 diabetes. 3,227 RCT Follow-up of UKPDS patients with Type 2 diabetes 10.7 years HbA1c was 7.4% in the metformin group compared to 8.0% in the conventional group. Compared to the conventional group the patients in the metformin group, had a risk reduction of: - 32% for any diabetes-related end-point (95% CI: 13 to 47; P=0.002) - 42% for diabetes-related death (95% CI: 9 to 63; P= ) - 36% for all-cause mortality (95% CI: 9 to 55; P=0.011) Metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint (P=0.0034); all-cause mortality (P=0.021); and stroke (P=0.032). 10 years In the sulfonylurea-insulin group, relative reductions in risk persisted for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001). Risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) also emerged over time. The metformin group also showed significant risk reductions for any diabetesrelated end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). Plasma creatinine levels in the metformin group were 15% higher on average than those in the conventional-therapy group (P<0.04) Sasaki et al (1989)[9] 1,196 Retrospective Cohort Type 2 diabetic patients from the Osaka Medical Centre for Adult Diseases, Japan ( ) 740 males, 456 females 10 years Of the193 patients who developed persistent albuminuria, 66 (34%) died, before the end of the observation period, with a mean survival period of years after the onset of persistent albuminuria. Mean annual incidence rates of persistent albuminuria differed considerably depending on the type of treatment patients were on at baseline (10.74% for diet versus 19.47% oral hypoglycaemic versus 40.78% for insulin). Renal disease was the predominant cause of death in patients who developed persistent albuminuria, followed by heart disease and cerebrovascular disease. Early Chronic Kidney Disease July 2012 Page 7 of 9
8 Table 1a. Characteristics of included randomised controlled trials Study ID (author, year) Trial Research Group (1993) [DCCT] [3] N Study Design Setting Participants Intervention (experimental group) 1,441 Randomised controlled clinical trial 3,867 Randomised controlled clinical trial 29 centres, US Patients with IDDM +/- retinopathy 23 centres UK Participants newly diagnosed with Type 2 Diabetes Mellitus Intensive insulin therapy (insulin pump or >3 daily injections & glucose monitoring) Sulphonylurea, or insulin Intervention (control group) Conventional therapy (1 to 2 daily insulin injections) Conventional therapy with diet Follow up (months) Comments 78 Two study cohorts, randomised to intervention and control groups. Total of 4 treatment arms 120 A sub-study was conducted in overweight patients with type 2 diabetes, treated with intensive glucose control and metformin vs conventional treatment. Table 2. Methodological quality of randomised trials Study ID (author, year) Trial Research Group (1993) [DCCT][3] Method of Blinding Intention-totreat Loss to Comments allocation concealment * (participants) (investigators) (outcome assessors) analysis follow up (%) Not specified No No No No 3.0 _ Central and sealed, opaque envelopes which were opened in sequence No No No Yes Not specified Ø * Choose between: central; third party (e.g. pharmacy); sequentially labelled opaque sealed envelopes; alternation; not specified. Choose between: yes; no; unclear. Quality score How successfully do you think the study minimised bias? Choose between: very well (+); okay (Ø); poorly ( ). Early Chronic Kidney Disease July 2012 Page 8 of 9
9 Table 3a Results and quality rating for dichotomous outcomes Outcomes Study ID (author, year) Intervention group (no. of patients with events/no. of patients exposed) Control group (no. of patients with events/no. of patients exposed) Relative risk (RR) [95% CI] Risk difference (RD) [95% CI] Importance** Nephropathy Urinary albumin excretion (UAE) 40 mg/24hr Trial Research Group (1993) [DCCT][3] 2.2 rate/100 patient-yr (Primary prevention group) 3.6 rate/100 patient-yr (Secondary intervention group) 3.4 rate/100 patient-yr Risk reduction 34% (2 56) 5.7 rate/100 patient-yr Risk reduction 43% (21 58) Not provided Not provided Important All-cause mortality 489/ / (0.83, 1.11) (-0.03, 0.02) Critical Death from renal disease 8/2729 2/ (0.35, 7.84) 0.00 (-0.00, 0.00) Critical Renal Failure 16/2729 9/ (0.33, 1.67) * Methodological quality, consistency across studies and directness of the evidence (generalisability/applicability). ** The GRADE system uses the following 3 categories to rank the importance of end points: critical for decision making important but not critical for decision making not important for decision making (of lower importance to patients) (-0.01, 0/00) Critical Early Chronic Kidney Disease July 2012 Page 9 of 9
Understanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationUse of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical
More informationNational Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes
National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes Prepared by: The Boden Institute of Obesity, Nutrition and Exercise The University of Sydney In collaboration with: The Diabetes
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationDiabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationPROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT
DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT Diabetic nephropathy affects people with either type 1 or type 2 diabetes mellitus.
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationRenal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationMeasure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care
Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationUsing a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes
Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH
More informationSummary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06
CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationPrevention and management of chronic kidney disease in type 2 diabetes
162..194 NEPHROLOGY 2010; 15, S162 S194 doi:10.1111/j.1440-1797.2010.01240.x Prevention and management of chronic kidney disease in type 2 diabetes Date written: April 2009nep_1240 Final submission: April
More informationSafety & Effectiveness of Drug Therapies for Type 2 Diabetes: Are pharmacoepi studies part of the problem, or part of the solution?
Safety & Effectiveness of Drug Therapies for Type 2 Diabetes: Are pharmacoepi studies part of the problem, or part of the solution? IDEG Training Workshop Melbourne, Australia November 29, 2013 Jeffrey
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationDiabetes and the Kidneys
Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationIn many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationComplicanze del diabete nel bambino e nell adolescente
Clinica Pediatrica Università di Chieti Complicanze del diabete nel bambino e nell adolescente Franco Chiarelli XVII Congresso Nazionale SIPPS Parma, 25 Novembre 2005 Type 1 diabetes in childhood: Only
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationHow To Know If Low Protein Diet Is Beneficial For Kidney Health
Protein Intake and Diabetic Kidney Disease Robert C. Stanton Joslin Diabetes Center 1/Serum Creatinine Plot Low Protein Protects in Renal Ablation Model 24% Protein Diet 6% Protein Diet Right Nephrectomy
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationEpidemiology of Diabetic Kidney Disease
Epidemiology of Diabetic Kidney Disease Anne T. Reutens, MBBS, PhD, FRACP a,b, * KEYWORDS Diabetes Prevalence Incidence Microalbuminuria Macroalbuminuria End-stage renal disease KEY POINTS Diabetic kidney
More informationMicroalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?
Focus on CME at the University of Saskatchewan Microalbuminuria: So What s a Little Protein? By Judith T. Klassen, BSc, MD, FRCPC University of Saskatchewan Practical Management of Common Medical Problems
More informationHow To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationInsulin detemir versus insulin glargine for type 2 diabetes mellitus (Review)
Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Review) Swinnen SG, Simon ACR, Holleman F, Hoekstra JB, DeVries JH This is a reprint of a Cochrane review, prepared and maintained
More informationDiabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
More informationLinköping University Post Print
Linköping University Post Print Can diabetes medication be reduced in elderly patients?: An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control Peter Sjöblom,
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationAppropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
Appropriate in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Robert W Schrier*, Raymond O Estacio, Philip S Mehler and William R Hiatt SUMMARY The hypertensive and
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationCriteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationGlycemic Control of Type 2 Diabetes Mellitus
Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Glycemic Control of Type 2 Diabetes Mellitus Majeda Fikree* Baderuldeen Hanafi** Zahra Ali Hussain** Emad M Masuadi*** Objective: To determine the
More informationPrevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한
Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한 Introduction CKD의 정의와 egfr의 측정 CKD의 risk factor와 mechanism 한국의 CKD prevalence 와 prognosis CKD의 치료와
More information10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationScottish Diabetes Survey 2013. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2013 Scottish Diabetes Survey Monitoring Group Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 18 Duration of Diabetes... 18
More informationScottish Diabetes Survey 2014. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2014 Scottish Diabetes Survey Monitoring Group Contents Table of Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 21 Duration
More information[Frida Svendsen and Jennifer Southern] University of Oxford. October 2014
In adolescents with poorly controlled type 1 diabetes mellitus, could a bionic, bihormonal pancreas provide better blood glucose control than continuous subcutaneous insulin infusion therapy? [Frida Svendsen
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM
ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM Management of Traditional Cardiovascular Risk Factors in ESRD (Hypertension, Dyslipidemia, Glycemic Control) ROBERT D. TOTO, M.D. PROFESSOR OF MEDICINE
More informationIncidence of Complications in Insulin-dependent Diabetes Mellitus: A Survival Analysis
American Journal of Epidemiology Copyright O 1996 by The Johns HopWns University School of Hygiene and Public Health All rights reserved Vol. 143, No. 5 Printed In U.S.A Incidence of Complications in Insulin-dependent
More informationType 2 Diabetes workshop notes
Group 1 notes Abi / Nicole Type 2 Diabetes workshop notes 4.1 Population The group discussed the following sub groups that may need addressing: Men-as they tend to die earlier compared with women, their
More informationPrediction of Kidney Disease Progression in Patients with Diabetes
Prediction of Kidney Disease Progression in Patients with Diabetes John Arthur, MD, PhD Medical University of South Carolina SEKDC Meeting September 8, 2012 Objectives Understand the importance of predicting
More informationType 2 Diabetes. Type 2 Diabetes. Diabetes Complications. Global Telehealth Conference 2012
Effects of Type 2 Diabetes Behavioural Telehealth Interventions on Glycaemic Control & Adherence: A Systematic Review Mandy Cassimatis & David Kavanagh Type 2 Diabetes Diabetes 273 Australians/ day 85
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More information( Diabetic nephropathy) ( Microalbuminuria ) ( Macroalbuminuria )
2006 17 99-105 2006 20-40% ( ESRD ) 30 299 mg ( ) ( 300 mgday ) DCCBs ) dihydropyridine calcium channel blockers ( non- DCCBs ( -blockers ( diuretics ) 10%) 0.8 ( 60 mlmin per 1.73 m 2 30 mlmin per 1.73
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationImproving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge
Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages
More informationAlbuminuria versus GFR as markers of diabetic CKD progression
Albuminuria versus GFR as markers of diabetic CKD progression KDIGO Controversies Conference: Diabetic Kidney Disease New Delhi, March 2012 Richard J MacIsaac PhD FRACP Director of Endocrinology & Diabetes,
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationDRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationPrevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy
Prevalence and Characteristics of Low Serum Testosterone Levels in Men with Type 2 Diabetes Mellitus Naïve to Injectable Therapy International Society for Sexual Medicine 2014 Presenter: Felipe Borges
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationINSULIN REQUIREMENT IN DIABETIC PATIENTS WITH CHRONIC RENAL FAILURE DUE TO DIABETIC NEPHROPATHY (DN)
E:/Biomedica/New Journal 2004/Bio-11.doc (A) INSULIN REQUIREMENT IN DIABETIC PATIENTS WITH CHRONIC RENAL FAILURE DUE TO DIABETIC NEPHROPATHY (DN) KAMRAN RASHID, KHALIL UR REHMAN, M. SAEED ANWER AAEISHA
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationMafauzy Mohamad Health Campus University Sains Malaysia. Declared no potential conflict of interest
International guidelines for the management of diabetes: evidence based medicine vs personalized medicine Mafauzy Mohamad Health Campus University Sains Malaysia Declared no potential conflict of interest
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationPoorly controlled diabetes mellitus the way forward
Poorly controlled diabetes mellitus the way forward Presentation at HA Convention 2008 6 May, 2008 Dr. M K Cheung Associate Consultant Department of Family Medicine Community Care Division New Territories
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationType 2 Diabetes. Tabinda Dugal GP Day 4/05/16
Type 2 Diabetes Tabinda Dugal GP Day 4/05/16 Diabetes Diabetes.a growing health crisis in Britain 869m per year 10% of NHS budget Projections.. 5 million by 2025 Youngest patient? T2DM Type 2 diabetes
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More information1990 Life Insurance and Diabetes
ADS Position Statements 1990 Life Insurance and Diabetes John Carter, John Greenway, Royal Prince Alfred Hospital, Concord Hospital and Hornsby Hospital, NSW Page 1 LIFE INSURANCE AND DIABETES MELLITUS
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More information